Literature DB >> 33494922

Combination of Immunotherapy and Antiangiogenic Therapy in Cancer-a Rational Approach.

Sukhmani K Padda1, Karen L Reckamp2.   

Abstract

Mesh：

Substances：

Year:  2021        PMID： 33494922     DOI： 10.1016/j.jtho.2020.11.007

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  3 in total

Review 1.  Apatinib: A Novel Antiangiogenic Drug in Monotherapy or Combination Immunotherapy for Digestive System Malignancies.

Authors:  Haosheng Li; Haiyan Huang; Tao Zhang; Haoran Feng; Shaodong Wang; Yaqi Zhang; Xiaopin Ji; Xi Cheng; Ren Zhao
Journal:  Front Immunol       Date:  2022-06-29       Impact factor: 8.786

Review 2.  Second-Generation Jak2 Inhibitors for Advanced Prostate Cancer: Are We Ready for Clinical Development?

Authors:  Paul Beinhoff; Lavannya Sabharwal; Vindhya Udhane; Cristina Maranto; Peter S LaViolette; Kenneth M Jacobsohn; Susan Tsai; Kenneth A Iczkowski; Liang Wang; William A Hall; Scott M Dehm; Deepak Kilari; Marja T Nevalainen
Journal:  Cancers (Basel)       Date:  2021-10-17       Impact factor: 6.575

3.  Development and validation of a nomogram for evaluating the prognosis of immunotherapy plus antiangiogenic therapy in non-small cell lung cancer.

Authors:  Hao Huang; Yao Chen; Xuezi Weng; Sirou Li; Lin Zhang; Peisong Chen
Journal:  Cancer Cell Int       Date:  2022-08-21       Impact factor: 6.429
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.